Metraipolis › archive › dc_cf43298b8ffd

Augmenting interferon-β and anti-PD-L1 antibody bolsters non-ablative radiotherapy to leverage potent abscopal effect in metastatic cancers — Europe PMC PMID:42745921

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42745921
DOI
10.3389/fimmu.2026.1925859
License (as archived)
solo-consultazione
Archived
2026-10-16T07:06:31.593Z
SHA-256 of the archived text
e4ed9a892fafe27a4b8cbb6d8a2d6040595a916114e1a47fb2f357d87f2309b9
Stable URL of this page
https://metraipolis.com/documento/dc_cf43298b8ffd

How to cite

Augmenting interferon-β and anti-PD-L1 antibody bolsters non-ablative radiotherapy to leverage potent abscopal effect in metastatic cancers — Europe PMC PMID:42745921 — Europe PMC (en), https://europepmc.org/article/MED/42745921 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cf43298b8ffd (Metraipolis archive dc_cf43298b8ffd, sha256 e4ed9a892fafe27a4b8cbb6d8a2d6040595a916114e1a47fb2f357d87f2309b9)
BibTeX
@misc{dccf43298b8ffd,
  title = {Augmenting interferon-β and anti-PD-L1 antibody bolsters non-ablative radiotherapy to leverage potent abscopal effect in metastatic cancers — Europe PMC PMID:42745921},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42745921},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cf43298b8ffd; sha256 e4ed9a892fafe27a4b8cbb6d8a2d6040595a916114e1a47fb2f357d87f2309b9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42745921. Agents can read the archived copy with the MCP tool read_document.